<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39339994</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>26</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Analysis of the Impact of Inactivated A71 Vaccine on the Incidence of Hand-Foot-Mouth Disease in Pudong New Area, Shanghai.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">962</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12090962</ELocationID><Abstract><AbstractText>The aim of this study was to investigate the level of inactivated A71 (EV-A71) vaccination in Pudong New Area of Shanghai and its effects on the epidemiology and pathogen spectrum of hand-foot-mouth disease (HFMD) in this area, as well as to provide a basis for improving the prevention and control strategy of HFMD in this area. Data were collected from the "Comprehensive Management Cloud Platform for Immunization Program" system from December 2016 to December 2022. The data on HFMD cases from January 2012 to December 2022 were extracted from the "China Information System for Disease Control and Prevention". A total of 484,056 doses were administered. The vaccination rate of the first dose was 14.03%, and the full vaccination rate was 13.33%. There were significant differences between the first dose and the full vaccination rate in different years (<i>χ</i><sup>2</sup> = 46,538.831, <i>p</i> &lt; 0.001, <i>χ</i><sup>2</sup> = 50,013.946, <i>p</i> &lt; 0.001). A total of 91625 cases of HFMD were reported, including 58 severe cases, and no deaths. Before and after the administration of the inactivated EV-A71 vaccine, there were statistical differences in the distribution of HFMD cases in terms of gender, household registration, occupation, and age (<i>p</i> &lt; 0.001). The etiological surveillance results showed that the rate of enterovirus positivity was 84.15%, with 9.85% being EV-A71, 23.74% CV-A16, and 50.56% non-EV-A71 and non-CV-A16. The coverage rate of the inactivated EV-A71 vaccine in Pudong New Area was not high, and the incidence of HFMD showed a downward trend after the postmarketing of the vaccine. The majority of HFMD infections were non-EV-A71 and non-CV-A16, with CV-A6 accounting for the highest proportion. It is recommended to accelerate the development of combined vaccines to provide more antibody protection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Dandan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Wenmin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Weiping</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Pengfei</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Chuchu</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-4461-4111</Identifier><AffiliationInfo><Affiliation>Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Laibao</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Caoyi</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Number PWZxk2022-25</GrantID><Agency>Caoyi Xue</Agency><Country /></Grant><Grant><GrantID>Number GWVI-11.2-XD08</GrantID><Agency>Caoyi Xue</Agency><Country /></Grant><Grant><GrantID>Number PWRd2020-14</GrantID><Agency>Caoyi Xue</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">etiological surveillance</Keyword><Keyword MajorTopicYN="N">hand–foot–mouth disease</Keyword><Keyword MajorTopicYN="N">inactivated A71 vaccine</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Chinese Center for Disease Control and Prevention. The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39339994</ArticleId><ArticleId IdType="pmc">PMC11435847</ArticleId><ArticleId IdType="doi">10.3390/vaccines12090962</ArticleId><ArticleId IdType="pii">vaccines12090962</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yuan J.-J., Shen L., Wu J., Zou X.-R., Gu J.-Q., Chen J.-G., Mao L.-X. Enterovirus A71 Proteins: Structure and Function. Front. Microbiol. 2018;9:286. doi: 10.3389/fmicb.2018.00286.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2018.00286</ArticleId><ArticleId IdType="pmc">PMC5826392</ArticleId><ArticleId IdType="pubmed">29515559</ArticleId></ArticleIdList></Reference><Reference><Citation>Nassef C., Ziemer C., Morrell D.S. Hand-foot-and-mouth disease: A new look at a classic viral rash. Curr. Opin. Pediatr. 2015;27:486–491. doi: 10.1097/MOP.0000000000000246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOP.0000000000000246</ArticleId><ArticleId IdType="pubmed">26087425</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.-Y., Zeng J., Zhang X.-P., Gan Z.-K., Fan J.-Q., Chen Y.-P., Liang Z.-Z., Hu X.-S., Zeng G., Lv H.-K. Short-term dynamic changes in neutralizing antibodies against enterovirus 71 after vaccination. Hum. Vaccines Immunother. 2020;16:1595–1601. doi: 10.1080/21645515.2020.1711678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2020.1711678</ArticleId><ArticleId IdType="pmc">PMC7482867</ArticleId><ArticleId IdType="pubmed">31977278</ArticleId></ArticleIdList></Reference><Reference><Citation>Departmental Documents of The State Council  Notice on the Issuance of Hand, Foot and Mouth Disease Guidelines for Diagnosis and Treatment (2018 Edition)  [(accessed on 23 May 2024)]; Available online:  https://www.gov.cn/zhengce/zhengceku/2018-12/31/content_5435156.htm.</Citation></Reference><Reference><Citation>Hu Y.-M., Zeng G., Chu K., Zhang J., Han W.-X., Zhang Y., Li J., Zhu F.-C. Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: A further observation. Hum. Vaccines Immunother. 2018;14:1517–1523. doi: 10.1080/21645515.2018.1442997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2018.1442997</ArticleId><ArticleId IdType="pmc">PMC6037439</ArticleId><ArticleId IdType="pubmed">29482422</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L.-D., MO Z.-J., Liang Z.-L., Zhang Y., Li R.-C., Ong K.-C., Wong K.-T., Yang E., Che Y.-C., Wang J.-J., et al. Immunity and clinical efficacy of an inactivated enterovirus 71 vaccine in healthy Chinese children: A report of further observations. BMC Med. 2015;13:226. doi: 10.1186/s12916-015-0448-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-015-0448-7</ArticleId><ArticleId IdType="pmc">PMC4574357</ArticleId><ArticleId IdType="pubmed">26381232</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F.-C., Liang Z.-L., Li X.-L., Ge H.-M., Meng F.-Y., Mao Q.-Y., Zhang Y.-T., Hu Y.-M., Zhang Z.-Y., Li J.-X., et al. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: A randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet. 2013;381:1037–1045. doi: 10.1016/S0140-6736(12)61764-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)61764-4</ArticleId><ArticleId IdType="pubmed">23352749</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan B.-X., Yan B.-F., Wang T.-H., Tian X.-Y., Ma L.-J., Zhang G.-Q., Luo L.-R., Jiang W.-G., Sun X.-H. Changes in occurrence and etiology of hand-foot-and-mouth disease in Jining City before and after EV-71 vaccination. Chin. J. Infect. Control. 2022;21:977–983.</Citation></Reference><Reference><Citation>Yang F., Liang W.-J., Sun L.-M., Long Y.-F., Zhang M., Li H., Zeng H.-R., Zheng H.-Y., Zheng H.-Z., Zhu Q. Innoculation of enterorirus 71 vaccine and incidence of hand-foot-mouth disease in Guangdong province. Chin. J. Public Health. 2020;36:351–354.</Citation></Reference><Reference><Citation>Lai H.-B., Wang J., Chen Q.-L., Chen W.-L. Incidence of hand, foot and mouth disease and effect of enterovirus 71 vaccine vaccination in Yunfu city of Guangdong Province, 2015–2019. Mod. Prev. Med. 2021;48:2268–2271.</Citation></Reference><Reference><Citation>Yao H.-C., Zhou J., Dong Z.-P., Sun Q.-S., Wu H.-Y., Du J.-R., Tang X.-H., Li S.-H. Coverage of inactivated enterovirus 71 vaccine and analysis of epidemiological and etiological changes of hand-foot-mouth disease before and after vaccination in Jinshan District of Shanghai. Chin. J. Biol. 2023;36:315–320.</Citation></Reference><Reference><Citation>Napolitano F., Della P.G., Angelillo I.-F. Knowledge, Attitudes, and Behaviors of Parents towards Recommended Adult Vaccinations: An Explanatory Survey in the Geographic Area of Naples, Italy. Int. J. Environ. Res. Public Health. 2019;16:2070. doi: 10.3390/ijerph16122070.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph16122070</ArticleId><ArticleId IdType="pmc">PMC6616468</ArticleId><ArticleId IdType="pubmed">31212739</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Pei T.-T., Lu J.-N., He X.-D., Zhuang J.-L. Analysis of Willingness and Influencing Factors of Children’s Parents to Receive Inactivated Enterovirus 71 Vaccine in Changning District of Shanghai. Health Educ. Health Promo. 2024;19:58–61.</Citation></Reference><Reference><Citation>Xu W.-J. Master’s Thesis. NingBo University; Ningbo, China: 2021. Jun 8, Epidemiological Characteristic change of Hand, Foot and Mouth Disease in Zhejiang Province after the Incubation, and Evaluation of Vaccine Effectiveness and Vaccine Impact for the EV-A71 Vaccine.</Citation></Reference><Reference><Citation>World Health Organization  Vaccine Efficacy, Effectiveness and Protection.  [(accessed on 5 June 2024)].  Available online:  https://www.who.int/news-room/feature-stories/detail/vaccine-efficacy-effectiveness-and-protection.</Citation></Reference><Reference><Citation>Ma E., Fung C., Yip S.H.L., Wong C., Chuang S.K., Tsang T. Estimation of the basic reproduction number of enterovirus 71 and coxsackievirus A16 in hand, foot, and mouth disease outbreaks. Pediatr. Infect. Dis. J. 2011;30:675–679. doi: 10.1097/INF.0b013e3182116e95.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0b013e3182116e95</ArticleId><ArticleId IdType="pubmed">21326133</ArticleId></ArticleIdList></Reference><Reference><Citation>Jian M.-T., Liao M.-T., Chen Z.-P., Zhi W. Epidemiological Characteristics of Hand, Foot and Mouth Disease in Zhaoqing from 2010 to 2019 and Effectiveness for EV71 Vaccine. Chin. Prim. Health Care. 2023;37:89–92.</Citation></Reference><Reference><Citation>Liu Y.-Q., Zhen H.-R., Bao Y., Lv Q., Qi Q., Hao C.-X., Liao X.-C., Zhang C.-Y. Situation of EV-A71 vaccination and epidemiological characteristics of hand-foot-mouth disease in Sichuan Province. J. Prev. Med. Info. 2022;38:1069–1075.</Citation></Reference><Reference><Citation>Xu Z.-Y., Wang X., Zhang L.-P., Lv J., Li X.-C., Liu N., Lu J., Su H.-L., Zeng M., Wu M. Health and economic evaluation of entervirus 71 vaccine immunization on HFMD in Minhang District of Shanghai from 2016 to 2018. Shanghai J. Prev. Med. 2021;33:404–409.</Citation></Reference><Reference><Citation>Jiang H.-C., Zhang Z., Rao Q., Wang X.-D., Wang M.-F., Du T.-Y., Tang J.-L., Long S.-Y., Zhang J., Luo J., et al. The epidemiological characteristics of enterovirus infection before and after the use of enterovirus 71 inactivated vaccine in Kunming, China. Emerg. Microbes Infect. 2021;10:619–628. doi: 10.1080/22221751.2021.1899772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1899772</ArticleId><ArticleId IdType="pmc">PMC8018479</ArticleId><ArticleId IdType="pubmed">33682641</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Z.-Q., Sui Y., Hou R.-J., Nie Z.-P., Song C.-Q., Gao X.-J., Zhao J.-J. Epidemiological characteristics and pathogenic changes of hand-footmouth disease before and after the launch of EV71 vaccine in Puyang city, Henan province. Mod. Dis. Control Prev. 2023;34:664–667.</Citation></Reference><Reference><Citation>Departmental Documents of The State Council  Hand, Foot and Mouth Disease Prevention and Control Guidelines (2008 Edition)  [(accessed on 29 May 2024)]; Available online:  http://www.nhc.gov.cn/jkj/s3577/200805/e73df45b7b1549188b1d4e1efd604da9.shtml.</Citation></Reference><Reference><Citation>Sheng S., Zhang K.-X., Huang B.-J. Comparative analysis of epidemiological and etiological characteristics of hand-foot-mouth disease before and after EV71 vaccination in Xinwu District, Wuxi. J. Public Health Prev. Med. 2021;32:80–83.</Citation></Reference><Reference><Citation>Ye L.-X., Chen J.-P., Fang T., Ma R., Wang J.-M., Pan Z.-Q., Dong H.-J., Xu G.-Z. Vaccination coverage estimates and utilization patterns of inactivated enterovirus 71 vaccine post vaccine introduction in Ningbo, China. BMC Public Health. 2021;21:1118. doi: 10.1186/s12889-021-11198-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-021-11198-6</ArticleId><ArticleId IdType="pmc">PMC8194148</ArticleId><ArticleId IdType="pubmed">34112128</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J.-J., Feng Y., Liang S., Liu X.-F., Su L., Zhang X.-S., Liu D.-P. Surveillance and model prediction of hand, foot and mouth disease in Gansu, 2010–2021. Dis. Surveill. 2024;39:318–323.</Citation></Reference><Reference><Citation>China CDC Weekly  Evolutionary Diversity of Coxsackievirus A6 Causing Severe Hand, Foot, and Mouth Disease—China, 2012–2023.  [(accessed on 29 May 2024)].  Available online:  https://weekly.chinacdc.cn/en/article/doi/10.46234/ccdcw2024.086.</Citation><ArticleIdList><ArticleId IdType="doi">10.46234/ccdcw2024.086</ArticleId><ArticleId IdType="pmc">PMC11150167</ArticleId><ArticleId IdType="pubmed">38846357</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C.-W., Zeng Y., Liang C.-W., Sun H., Bi Z.-Y. Pathogen surveillance characteristics of HFMD in Nanningfrom 2018 to 2022. J. Prev. Med. Info. 2024. in press .</Citation></Reference><Reference><Citation>Lu H.-H., Xiao J.-B., Yan D.-M., Ji T.-J., Yang Q., Zhu S.-L., Zhang Y. Pathogenic Spectrum and CVA6 Gene Characteristics of 882 Severe Hand, Foot, and Mouth Disease from 2012 to 2023. Chin. J. Virol. 2024;40:383–391.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>